Singapore markets closed

OpGen, Inc. (OPGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.7366+0.0191 (+2.67%)
As of 03:11PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.7175
Open0.6700
Bid0.7059 x 100
Ask0.7719 x 100
Day's range0.6500 - 0.7500
52-week range0.1650 - 3.8400
Volume1,400,424
Avg. volume1,612,518
Market cap7.376M
Beta (5Y monthly)-0.79
PE ratio (TTM)N/A
EPS (TTM)-6.2500
Earnings date28 Mar 2024 - 02 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    OpGen Announces Acquisition of Preferred Stock by David Lazar

    David Lazar invests $3 million in Preferred StockNew OpGen Board of Directors appointedDavid Lazar will take over as CEO of OpGenOpGen settles outstanding liabilities with EIB ROCKVILLE, Md., March 25, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), announced today that the Company entered into a securities purchase agreement with David E. Lazar, an experienced private investor, pursuant to which he will acquire 3,000,000 shares of Series E Convertible Preferred St

  • GlobeNewswire

    OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update

    Total revenue for the first nine months of 2023 was approximately $2.35 million compared to approximately $1.89 million in the first nine months of 2022Implemented certain cash management initiatives, including restructuring U.S. operations by reducing headcount during the third quarter of 2023Signed preferred stock purchase agreement with a potential strategic investor in October 2023Entered into a warrant inducement agreement with an institutional investor in October 2023Subsidiaries Curetis G

  • Zacks

    Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics

    Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics are part of the Zacks Screen of the Week article.